Bioavailability is a pharmacokinetic construct describing the fraction of an administered dose that reaches the systemic circulation as parent compound. For an orally administered drug, this quantity reflects several sequential processes rather than a single absorption event. Absorption determines how much drug crosses the gastrointestinal barrier and becomes available for portal delivery, while intestinal and hepatic presystemic metabolism can remove a fraction before it reaches systemic circulation. First-pass handling therefore links absorption extent with metabolic extraction, producing a systemic input fraction that becomes the starting quantity for subsequent plasma exposure. Bioavailability should be distinguished from the rate of input, because two compounds can have different systemic fractions while also differing in the timing of that input. It is also distinct from distribution, elimination, concentration–effect relationships, and any downstream interpretation of exposure. For sildenafil and avanafil, mechanistic comparison therefore examines the sequence from administered dose to absorbed fraction, presystemic loss, and systemic parent-drug entry rather than treating bioavailability as an outcome measure. This framework connects the page to the broader PK structure described in overview.
Sildenafil and avanafil can be compared mechanistically through the determinants that connect oral administration with systemic parent-drug exposure. Differences in absorption extent alter the quantity available for portal delivery, while differences in presystemic metabolic turnover alter the fraction surviving intestinal and hepatic first-pass handling. Both compounds undergo substantial CYP3A4-mediated metabolism, with CYP2C9 providing a smaller metabolic contribution for sildenafil and a minor contribution for avanafil. These pathways affect systemic input when metabolism occurs before parent drug reaches systemic circulation. Distribution begins after systemic entry and does not itself define absolute oral bioavailability, but it can reshape the resulting concentration-time profile through movement between plasma and tissue compartments. The resulting input geometry contributes to the ascending exposure region relevant to onset comparison, the concentration profile considered in peak effect comparison, and the persistence and decline considered in duration comparison. The underlying determinants are further separated into absorption differences and metabolism differences.
Bioavailability variability is primarily a PK concept when the source of variation lies in absorption, presystemic metabolism, hepatic extraction, or related disposition parameters. Differences in gastrointestinal input can change the absorbed fraction or the timing of systemic entry, while variability in metabolic turnover can change the fraction surviving presystemic extraction. Hepatic blood flow, enzyme activity, substrate availability, and other model parameters can consequently alter systemic parent-drug exposure. Distribution variability can further change plasma concentration geometry after systemic entry without necessarily changing the original fraction absorbed. These mechanisms belong to pk variability. PD variability represents a separate layer: changes in concentration–effect potency, slope, or maximal modeled effect can modify the relationship between a given systemic concentration and modeled response without changing bioavailability itself. This distinction is important because an identical systemic input fraction can coexist with different concentration–effect parameters. Conversely, different bioavailability can produce different exposure trajectories while the underlying PD parameters remain unchanged. The interaction between these layers is therefore best represented as PK input variability coupled to, but conceptually distinct from, pd variability.
Oral bioavailability can be represented mechanistically as the product of processes governing the fraction absorbed and the fraction that survives presystemic extraction before entering systemic circulation. Absorption extent describes the fraction of administered drug that becomes available beyond the gastrointestinal lumen, while intestinal availability describes the fraction that escapes intestinal metabolism and transport-related loss. The remaining systemic input is then influenced by hepatic first-pass extraction, including CYP-mediated metabolic turnover. For sildenafil, CYP3A4 is the principal metabolic pathway, with CYP2C9 contributing to a lesser extent. Avanafil is also predominantly metabolized through CYP3A4, with CYP2C9 representing a minor pathway. These pathways can therefore influence the parent-drug fraction reaching systemic circulation when metabolism occurs before systemic entry. The resulting systemic input fraction establishes the amount of parent compound available to generate the subsequent plasma concentration-time trajectory. Bioavailability should consequently be separated from absorption rate: extent determines how much enters, whereas input rate determines how rapidly that entry occurs. The relevant mechanistic distinctions are developed further in absorption differences and metabolism differences.
For sildenafil and avanafil, differences in absorption extent and presystemic metabolic handling can be represented as differences in the fraction of administered parent drug entering systemic circulation. A larger absorbed fraction does not necessarily imply an identical systemic fraction because intestinal and hepatic extraction can remove drug before systemic entry. Likewise, a difference in metabolic turnover can alter systemic input without requiring a difference in the initial amount absorbed. Once parent drug enters systemic circulation, distribution determines how that input is partitioned between plasma and tissue compartments. Distribution therefore influences concentration-time geometry after bioavailability has established the systemic input, rather than serving as the primary definition of absolute bioavailability. These processes can be analyzed alongside distribution differences, while the persistence of the resulting exposure profile can be examined through duration comparison. Mechanistically, bioavailability is therefore an upstream determinant of systemic exposure quantity, while distribution and elimination shape how that quantity is expressed over time.
| Bioavailability Domain | Sildenafil | Avanafil | Link |
|---|---|---|---|
| Absorption Extent | Determines the fraction of administered drug becoming available for systemic input before presystemic loss. | Determines the fraction of administered drug becoming available for systemic input before presystemic loss. | absorption differences |
| Presystemic CYP3A4 | Major contributor to presystemic and systemic metabolic turnover; presystemic activity can reduce parent-drug systemic input. | Major contributor to metabolic turnover; presystemic activity can reduce parent-drug systemic input. | metabolism differences |
| CYP2C9 Contribution | Secondary metabolic pathway relative to CYP3A4. | Minor metabolic pathway relative to CYP3A4. | metabolism differences |
| Intestinal Availability | Fraction of absorbed drug surviving intestinal loss and becoming available for portal delivery. | Fraction of absorbed drug surviving intestinal loss and becoming available for portal delivery. | overview |
| Systemic Input Fraction | Fraction of administered parent drug reaching systemic circulation after absorption and presystemic handling. | Fraction of administered parent drug reaching systemic circulation after absorption and presystemic handling. | onset comparison |
The systemic input fraction established by bioavailability determines the amount of parent compound available to form the initial plasma concentration trajectory. That concentration trajectory subsequently interacts with pharmacodynamic parameters such as potency, concentration–effect slope, and maximal modeled effect. Potency defines the concentration scale associated with a specified modeled effect level, while slope determines how rapidly modeled effect changes as concentration changes. A greater or smaller systemic input fraction can therefore shift the concentration trajectory relative to a concentration–effect function without changing the intrinsic PD parameters themselves. This distinction separates a PK change in the amount entering systemic circulation from a PD change in how concentration is translated into modeled effect. The initial concentration region can consequently differ even when the underlying concentration–effect relationship is held constant. Conversely, a change in potency or slope can modify the modeled effect associated with the same concentration trajectory without changing bioavailability. Bioavailability is therefore an upstream PK input determinant, whereas the concentration–effect relationship provides the subsequent PD mapping.
PK and PD variability represent different sources of variation in the mechanistic relationship between administered dose and modeled effect. PK variability can alter absorption extent, presystemic extraction, systemic input, distribution, metabolic turnover, or clearance, thereby changing the concentration-time trajectory. PD variability can instead alter potency, slope, or maximal modeled effect while the PK concentration trajectory remains unchanged. Consequently, two modeled systems with identical bioavailability can produce different concentration–effect relationships if PD parameters vary. Conversely, two systems with identical PD parameters can generate different modeled effect trajectories if bioavailability or other PK parameters differ. This separation is captured by pk variability and pd variability. The interaction is therefore sequential but coupled: bioavailability establishes an upstream systemic concentration input, disposition transforms that input into a time-dependent concentration profile, and PD parameters map concentration onto modeled effect. No single layer should be treated as equivalent to the others.
| PD Domain | Bioavailability Interaction Determinant | Link |
|---|---|---|
| Potency | Determines the concentration scale at which a given modeled effect is represented. | pd variability |
| Slope | Determines the modeled rate of effect change as concentration changes. | pd variability |
| Maximal Modeled Effect | Defines the upper asymptotic limit of the modeled concentration–effect relationship and is distinct from systemic input fraction. | duration comparison |
Mechanistic bioavailability differences arise from the sequence connecting the administered dose to systemic parent-drug entry. The principal determinants include the extent of gastrointestinal absorption, intestinal availability, presystemic metabolic loss, hepatic first-pass extraction, and the resulting fraction of parent compound entering systemic circulation. Sildenafil and avanafil are both substantially metabolized through CYP3A4, while CYP2C9 contributes more substantially to sildenafil metabolism and only to a minor extent for avanafil. These enzyme pathways can influence systemic input when metabolism occurs before the parent compound reaches systemic circulation. Bioavailability is therefore a composite PK quantity rather than a direct measure of absorption alone. Distribution occurs after systemic entry and can reshape the plasma concentration-time profile without defining the original absolute bioavailability fraction. Similarly, elimination controls subsequent decline rather than the initial fraction entering circulation. The comparison is therefore based on mechanistic differences in absorption and presystemic handling, not on downstream clinical outcomes or performance.
Absorption extent determines how much of an orally administered dose crosses the gastrointestinal barrier and becomes available for portal delivery. The absorbed amount is then subject to intestinal and hepatic presystemic handling. Metabolic extraction before systemic entry removes a portion of parent compound, so the systemic input fraction depends on both the amount absorbed and the fraction that survives presystemic loss. A compound with extensive absorption can still have a smaller systemic parent-drug fraction if presystemic extraction is substantial. Conversely, reduced presystemic extraction can increase the fraction reaching systemic circulation without requiring a change in the original absorption process. The timing of absorption is a separate parameter: absorption rate influences when systemic input occurs, whereas absorption extent and presystemic extraction influence how much parent compound enters. Once systemic entry occurs, distribution and elimination determine the subsequent concentration-time geometry. Bioavailability therefore describes the quantity reaching systemic circulation, while related PK parameters describe the timing and disposition of that quantity.
PK variability can directly alter bioavailability when variation occurs in absorption extent, intestinal availability, presystemic metabolic turnover, or hepatic extraction. Such variation changes the fraction of administered parent compound reaching systemic circulation and can consequently change the concentration-time trajectory. Distribution and clearance variability can further modify exposure geometry after systemic entry, although they are not identical to bioavailability. PD variability operates at a different level. Changes in potency, concentration-effect slope, or maximal modeled effect can alter the modeled response associated with a given concentration without changing the fraction of dose entering systemic circulation. Thus, bioavailability variability is primarily an upstream PK phenomenon, whereas PD variability concerns concentration-effect translation. The two layers can interact in a combined PK/PD model because a changed systemic concentration trajectory is evaluated through potentially variable PD parameters. Mechanistically, separating these sources prevents a change in modeled effect from being interpreted automatically as a change in bioavailability.
Bioavailability describes the fraction of administered parent drug that reaches systemic circulation, whereas peak and duration describe features of the resulting concentration-time trajectory. A systemic input fraction establishes the amount of parent compound entering circulation, but absorption rate determines the timing of that input, distribution determines how drug partitions between compartments, and clearance and metabolism determine subsequent decline. Peak concentration therefore depends on more than bioavailability alone, including the rate and extent of input and disposition processes. Duration likewise depends on persistence and decline of exposure rather than simply on the initial systemic fraction. Two modeled compounds can consequently have different bioavailability values while displaying overlapping or distinct peak and duration geometries depending on their absorption, distribution, metabolism, and clearance parameters. Keeping these constructs separate also prevents concentration-effect parameters from being conflated with PK input. Bioavailability is therefore an upstream quantitative descriptor of systemic parent-drug entry, while peak and duration are downstream properties of the evolving PK trajectory.